FY2025 EPS Forecast for Soleno Therapeutics Cut by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Stock analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for Soleno Therapeutics in a report released on Thursday, May 8th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($3.44) per share for the year, down from their prior forecast of ($2.85). Cantor Fitzgerald currently has a “Overweight” rating and a $123.00 target price on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.19.

Several other brokerages also recently weighed in on SLNO. Laidlaw boosted their price target on Soleno Therapeutics from $75.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, March 27th. Guggenheim lifted their price objective on Soleno Therapeutics from $81.00 to $97.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Piper Sandler increased their target price on Soleno Therapeutics from $93.00 to $145.00 and gave the stock an “overweight” rating in a research report on Thursday, April 24th. Stifel Nicolaus lifted their price target on Soleno Therapeutics from $74.00 to $108.00 and gave the company a “buy” rating in a report on Friday, March 28th. Finally, Robert W. Baird increased their price objective on shares of Soleno Therapeutics from $102.00 to $105.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $106.78.

Soleno Therapeutics Price Performance

NASDAQ:SLNO opened at $74.44 on Monday. The firm has a market cap of $3.75 billion, a PE ratio of -22.42 and a beta of -2.67. The firm has a 50 day simple moving average of $64.48 and a 200-day simple moving average of $54.66. Soleno Therapeutics has a 1-year low of $36.93 and a 1-year high of $80.99.

Institutional Trading of Soleno Therapeutics

Hedge funds have recently made changes to their positions in the company. Barclays PLC grew its stake in shares of Soleno Therapeutics by 149.3% during the third quarter. Barclays PLC now owns 52,545 shares of the company’s stock valued at $2,652,000 after acquiring an additional 31,467 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Soleno Therapeutics by 35.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 13,915 shares of the company’s stock valued at $703,000 after purchasing an additional 3,666 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in Soleno Therapeutics by 3.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 37,296 shares of the company’s stock worth $1,676,000 after purchasing an additional 1,248 shares during the last quarter. Avanza Fonder AB acquired a new position in shares of Soleno Therapeutics in the 4th quarter valued at approximately $76,000. Finally, Avior Wealth Management LLC purchased a new position in shares of Soleno Therapeutics during the 4th quarter valued at approximately $89,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Insider Activity

In other Soleno Therapeutics news, VP Michael F. Huang sold 14,583 shares of the firm’s stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $69.51, for a total value of $1,013,664.33. Following the transaction, the vice president now directly owns 36,817 shares of the company’s stock, valued at $2,559,149.67. This trade represents a 28.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Patricia C. Hirano sold 3,782 shares of the company’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $70.11, for a total value of $265,156.02. Following the completion of the sale, the insider now directly owns 27,036 shares of the company’s stock, valued at $1,895,493.96. The trade was a 12.27% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 942,672 shares of company stock valued at $64,058,781 in the last three months. Corporate insiders own 12.30% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.